Mylan Confident On Advair Generic First-Round Approval
Executive Summary
President Rajiv Malik said there has been “huge movement” at the agency around executing on the first ANDA for a generic version of GlaxoSmithKline’s blockbuster Advair.
You may also be interested in...
Mylan's Cold-Eeze OTC Acquisition Aims To Leverage Respiratory Expertise
Mylan could tap respiratory product experience to develop line extensions to the homeopathic product, now seen as the centerpiece of its US consumer business.
Advair: A Big Generic Opportunity And A Big Question Mark In 2017
Takeda’s Velcade, Pfizer’s Viagra and Gilead’s Viread are among the brand drugs expected to face generic competition in the US for the first time in 2017. One unknown is if FDA will approve Mylan’s or Hikma’s ANDAs for a generic version of GSK’s Advair.
Advair: A Big Generic Opportunity And A Big Question Mark In 2017
Takeda’s Velcade, Pfizer’s Viagra and Gilead’s Viread are among the brand drugs expected to face generic competition in the US for the first time in 2017. One unknown is if FDA will approve Mylan’s or Hikma’s ANDAs for a generic version of GSK’s Advair.